Press Release: Sanofi and Orano join forces to develop
next-generation radioligand medicines
Sanofi and Orano join forces to develop
next-generation radioligand medicines
Paris, October 17, 2024. Sanofi
and Orano Med, a subsidiary of the Orano Group and a pioneer in the
development of targeted alphatherapies in oncology, have entered
into an agreement to combine their expertise in the fight against
rare cancers and further accelerate the development of
next-generation radioligand medicines.
Building on the expertise and radioligand
pipeline of Orano Med, Sanofi and Orano will invest in a new
entity, operating under the Orano Med brand, and focusing on the
discovery, design, and clinical development of next-generation
radioligand therapies (RLTs) based on lead-212 (212Pb)
alpha-emitting isotopes. This agreement follows Sanofi’s
announcement of an exclusive licensing agreement with Orano Med and
RadioMedix to advance radioligand therapies (RLTs) in rare cancers
with a focus on one late-stage project, AlphaMedix™.
Targeted alpha therapy relies on a simple
concept: combining the ability of biological vectors to target
cancer cells with the short-range and highly energetic cell-killing
capabilities of alpha-emitting radioisotopes. The vector directs
the radioisotope to the target cancer cells expressing the specific
marker, even when they have spread throughout the body. This unique
mechanism of action aims to damage or destroy target cancer cells,
while limiting impact on nearby healthy cells. This novel precision
medicine approach aims at changing the standard of care in some
rare cancers to extend patients’ lives and improve their quality of
life.
Paul Hudson
CEO, Sanofi
“We are excited to partner with Orano in establishing
a French pioneer that unites our respective expertise in biopharma
and nuclear technology to drive groundbreaking progress in the
fight against cancer. As a French biopharmaceutical company, we are
deeply committed to fostering and enabling innovation in our home
country. This collaboration is part of a broader effort to
strengthen our ties within the scientific community, both in France
and globally, with the goal of advancing the development of
cutting-edge treatments for patients.”
Nicolas Maes
CEO, Orano Group
“The success of Orano Med is an example of our group's
ability to diversify beyond our core nuclear business. By applying
our expertise in nuclear materials to fields like targeted alpha
therapies, we are demonstrating that nuclear technology can have a
positive societal impact, not just for energy and climate, but also
for human health. This innovation reflects Orano's commitment to
exploring new opportunities and taking bold steps to address some
of the world’s most pressing challenges.”
Sanofi’s investment will further strengthen
Orano Med and allow the company to accelerate the development of
its pipeline, leveraging its unique capabilities in the discovery
and development of lead-212 based therapies. Orano Med has also
developed a highly differentiating global industrial platform,
which, thanks to its vast stock of raw materials and patented
manufacturing process, will ensure an independent, reliable, and
scalable supply of lead-212 based therapies to patients
worldwide.
Houman Ashrafian
Executive Vice President, Head of Research and Development,
Sanofi
“We are thrilled to invest in the promising field of
radioligand therapies, a modality that holds potential for patients
suffering from rare cancers. We see opportunity in the innovative
lead-212 based technologies being developed by Orano Med, which
align with our commitment to advancing transformative therapies for
unmet medical needs.”
Julien Dodet
President of the Governing Board, Orano Med
“Sanofi’s partnership with Orano Med is a strong
recognition of the potential of lead-212 based radioligand
therapies to advance the treatment of cancers. This validates our
strategy, having developed this expertise over the past 15 years,
and reinforces our position as a leader in targeted alpha
therapies. We look forward to combining Sanofi’s expertise with our
R&D and world-class radiopharmaceutical capabilities to advance
the development of potentially transformative therapies like
AlphaMedix and make them available to patients in need as quickly
as possible.”
In striving to become a leading immunoscience
company globally, Sanofi remains committed to advancing oncology
innovation. The pipeline is being reshaped and prioritized,
leveraging expertise in immunoscience to drive progress. Efforts
are centered on difficult-to-treat cancers such as select
hematologic malignancies and solid tumors with critical unmet
needs, including rare cancers such as multiple myeloma, acute
myeloid leukemia, and certain types of lymphomas, as well as
gastrointestinal and lung cancers.
Sanofi and Orano Med are members of the Paris
Saclay Cancer Cluster and look forward to contributing to the
ambitious agenda of the France 2030 plan to accelerate innovation
in oncology.
This agreement is subject to standard regulatory
approvals required for transactions of this nature.
Financial
considerations
Under the terms of the agreement, Sanofi will make an equity
investment of €300 million, approximately 16% equity stake in the
new entity valued at €1.9bn.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions. Sanofi is listed on EURONEXT: SAN and
NASDAQ: SNY
About Orano Med
Orano Med, a subsidiary of the Orano Group, is a clinical-stage
biotechnology company that develops a new generation of targeted
therapies against cancer using the unique properties of lead-212
(212Pb), an alpha-emitting radioisotope and one of the
more potent therapeutic payloads against cancer cells known as
Targeted Alpha-Emitter Therapy (TAT). The company is developing
several treatments using 212Pb combined with various
targeting agents. Orano Med has 212Pb manufacturing
facilities, laboratories, and R&D centers in France and in the
US and is currently investing to further expand its
GMP-manufacturing capacities for 212Pb radiolabeled
pharmaceuticals in North America and Europe.
As a recognized international operator in the
field of nuclear materials, Orano Group delivers solutions to
address present and future global energy and health challenges. Its
expertise and mastery of cutting-edge technologies enable Orano to
offer its customers high value-added products and services
throughout the entire fuel cycle. Every day, the Orano group’s
17,500 employees draw on their skills, unwavering dedication to
safety and constant quest for innovation, with the commitment to
develop know-how in the transformation and control of nuclear
materials, for the climate and for a healthy and resource-efficient
world, now and tomorrow.
Contacts
Orano Med
Sophie Letournel | +33 6 38 44 34 11|
sophie.letournel@orano.group
Orano Group
Press Office | +33 (0)1 34 96 12 15|
press@orano.group
Orano Investor relations
Marc Quesnoy | investors@orano.group
Sanofi Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 |
evan.berland@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 |
nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Sanofi Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Sanofi forward-looking
statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions, and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2023. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
All trademarks mentioned in this press release
are the property of the Sanofi group apart from AlphaMedix.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Dic 2023 a Dic 2024
